Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNU-201
- Development stage
- Preclinical
- Lead developer
- Gnubiotics Sciences
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Peptides, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GNU-201 is a preclinical, orally administered glycopeptide-based immunotherapy, developed on Gnubiotics’ GLAAD (glycopeptides with adjuvant and tumor‑associated antigen delivery) platform to treat solid tumors characterized by altered O-glycan profiles.[2][3][4] As a modular glycopeptide bearing a range of tumor-mimicking glycans covalently linked to peptide backbones, it is designed to provide both antigenicity and intrinsic adjuvanticity, directly modulating immune cells and the microbiome to drive robust CD8+ and CD4+ T‑cell responses and reduce immunosuppressive myeloid populations.[2][4] In colorectal cancer mouse models, oral supplementation with GNU-201 alone or combined with anti‑PD‑1 antibodies significantly reduced tumor growth and enhanced tumor-infiltrating effector and memory T cells, supporting its development as a first‑in‑class immunomodulatory and microbiome-modulating therapy for immune checkpoint inhibitor–resistant or non‑responding solid tumors.[2][3][4][5]
- Other names
- GLAAD glycopeptide GNU-201
Beyond the preview
Go deeper on GNU-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNU-201.